By Marie Rosenthal, MS
Health care teams from a variety of HIV clinics in the United States reported that optimal implementation of long-acting cabotegravir-rilpivirine (CAB + RPV LA; Cabenuva, ViiV Healthcare) was achieved within one to three months, according to a presentation at the International AIDS Society Conference 2021 (IAS 2021), held virtually.